BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 196.27 |
| Open | 200.00 |
| Bid | 198.19 x 200 |
| Ask | 198.76 x 100 |
| Day's Range | 195.71 - 200.51 |
| 52 Week Range | 126.97 - 215.00 |
| Volume | |
| Avg. Volume | 277,566 |
| Market Cap | 21.943B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.94 |
| Earnings Date | Nov 07, 2024 - Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 273.43 |
PR NewswireBeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). Lymphoma, a type of blood cancer affecting millions of people worldwide, is the focus of WLAD, which serves as a key platform during Blood Cancer Awareness Month to educate the public on the emotional and physical challenges faced by those living with the disease.
Simply Wall St.SK hynix And 2 More Stocks Estimated To Be Trading Below Fair Value
As global markets grapple with concerns over economic slowdowns and fluctuating indices, investors are increasingly seeking opportunities in undervalued stocks. In such volatile times, identifying companies trading below their fair value can offer a strategic advantage for long-term growth.
Business WireBeiGene Announces Updates to Commercial Leadership Team
SAN MATEO, Calif., September 09, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25.
